XML 62 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements and Financial Instruments - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Apr. 05, 2019
Nov. 30, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss Statement Of Income Extensible List Not Disclosed Flag     fair value fair value  
Unrealized (loss) on equity securities still held     $ (39.1) $ (41.4) $ 0.0
Restrictions on selling common stock, period     6 months    
Level 3 | BioCryst Pharmaceuticals, Inc.          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Number of shares purchased (in shares)   3,846,000      
Cytokinetics Commercial Launch Funding | Level 3          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Interest rate volatility (as a percent)     30.00%    
Risk-adjusted discount rate (as a percent)     13.50%    
Preferred Shares | Debt Securities          
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Number of shares purchased (in shares) 2,495        
Change in control event, period     4 years    
Preferred shares, weighted average cost of capital       9.50%